<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418600</url>
  </required_header>
  <id_info>
    <org_study_id>HECT00406</org_study_id>
    <nct_id>NCT00418600</nct_id>
  </id_info>
  <brief_title>A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis</brief_title>
  <official_title>A Phase 4, Multi-Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® Capsules When Converting From Hectorol® Injection for the Treatment of SHPT in Stage 5 CKD Subjects on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Hectorol is a safe and effective treatment of secondary hyperparathyroidism in hemodialysis&#xD;
      patients. Hectorol (doxercalciferol capsules) is indicated for the treatment of secondary&#xD;
      hyperparathyroidism in patients with chronic kidney disease on dialysis and in pre-dialysis&#xD;
      patients with Stage 3 or Stage 4 chronic kidney disease. Hectorol (doxercalciferol injection)&#xD;
      is indicated for the treatment of secondary hyperparathyroidism in patients with chronic&#xD;
      kidney disease on dialysis.&#xD;
&#xD;
      This protocol will determine clinically appropriate doses of Hectorol (doxercalciferol&#xD;
      capsules) when converting subject from Hectorol (doxercalciferol injection.) The study will&#xD;
      enroll hemodialysis patients that have been controlled on intravenous Hectorol. the&#xD;
      information gained from this study will be a useful guide for physicians in managing CKD&#xD;
      Stage 5 patients for whom a change from intravenous to oral vitamin D administration is&#xD;
      appropriate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Conversion</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hectorol capsules at 1.0 times current injection dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hectorol capsules at 1.5 times current injection dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hectorol capsules at 2.0 times current injection dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hectorol® (doxercalciferol capsules)</intervention_name>
    <description>Hectorol capsules at 1.0 times current injection dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxercalciferol capsules, Hectorol®</intervention_name>
    <description>Hectorol capsules at 1.5 times current injection dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxercalciferol capsules, Hectorol® capsules</intervention_name>
    <description>Hectorol capsules at 2.0 times current injection dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject must be receiving hemodialysis three times per week for a minimum of six&#xD;
             months.&#xD;
&#xD;
          -  The subject must have been receiving Hectorol Injection for a minimum of 3 months. The&#xD;
             subject must have been on a stable dose regimen, three times per week administration&#xD;
             for a minimum of four weeks.&#xD;
&#xD;
          -  The central laboratory assessment must be within the following ranges: serum iPTH&#xD;
             between 150-600 pg/mL, inclusive; corrected calcium &lt; 10.0 mg/dL; phosphorus &lt; 7.0&#xD;
             mg/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the opinion of the Investigator, the subject currently has poorly controlled&#xD;
             diabetes mellitus, poorly controlled hypertension, active vasculitis, HIV infection,&#xD;
             or any other clinically significant, unstable medical condition.&#xD;
&#xD;
          -  Abnormal liver function as measured by ALT/AST greater than two times the upper limit&#xD;
             of normal (ULN).&#xD;
&#xD;
          -  The subject currently has malabsorption, severe chronic diarrhea, or ileostomy.&#xD;
&#xD;
          -  Any evidence of active malignancy except for basal cell carcinoma of the skin. A&#xD;
             history of malignancy is not an exclusion.&#xD;
&#xD;
          -  Current use of aluminum or magnesium based binders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Downey</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hectorol.com/docs/Hectorol%20Capsule%20PI%20Text_2006-01.pdf</url>
    <description>US FDA Approved Full Prescribing Information for Hectorol® Capsules</description>
  </link>
  <link>
    <url>http://www.hectorol.com/docs/Hectorol%20Injection%20PI%20Text_2006-01.pdf</url>
    <description>US FDA Approved Full Prescribing Information for Hectorol® Injection</description>
  </link>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2007</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Genzyme Corporation</organization>
  </responsible_party>
  <keyword>Secondary Hyperparathyroidism</keyword>
  <keyword>Hectorol® (doxercalciferol capsules)</keyword>
  <keyword>Hectorol® (doxercalciferol injection)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

